Full Press Release Details
Edgewise Therapeutics Appoints Commercial Biotech
Executive Christopher Martin to its Board of Directors
Boulder, Colo., (November 20, 2025) - Edgewise
Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology
veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including
marketing, sales, commercial operations, market access, trade and business development.
"We are thrilled to welcome Chris to our Board of Directors,"
said Kevin Koch, Ph.D., President and Chief Executive Officer. "His commercial expertise and launch leadership will be critical
as we prepare for our first commercial launch in Becker muscular dystrophy and advance our cardiovascular asset to Phase 3.
Prior to joining the Edgewise Board, Mr. Martin served as Chief
Commercial Officer for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October of 2025.
As CCO, Mr. Martin was responsible for building the commercial organization and launch strategy for the company's first product
launch, Ohtuvayre (ensifentrine). Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing
novel therapeutics for central nervous system conditions. Mr. Martin was instrumental in developing the commercial and marketing
strategy and the framework for launching their first commercial product, XCOPRI (cenobamate tablets). Until its acquisition by Melinta
Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company's
first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and
led the Xifaxan marketing team during the company's acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor
of Science in Financial Management from Clemson University.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical
company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in
muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal
myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator
for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development.
EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire
team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements.
Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise's
product candidates and programs, including sevasemten, EDG-7500 and EDG-15400; statements regarding Edgewise's ability to commercialize
sevasemten; statements regarding Edgewise's ability to advance its cardiovascular asset to Phase 3; and statements by Edgewise's
President and Chief Executive Officer. Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking
statements. The forward-looking statements contained herein are based upon Edgewise's current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking
statements due to numerous risks and uncertainties, including but not limited to: risks associated with Edgewise's limited operating history,
its products being early in development and not having products approved for commercial sale; risks associated with Edgewise not having
generated any revenue to date; Edgewise's ability to achieve objectives relating to the discovery, development and commercialization of
its product candidates, if approved; Edgewise's need for substantial additional capital to finance its operations; Edgewise's substantial
dependence on the success of sevasemten and EDG-7500; Edgewise's ability to develop and commercialize sevasemten, EDG-7500 and EDG-15400;
risks related to Edgewise's clinical trials of its product candidates not demonstrating safety and efficacy; risks related to Edgewise's
product candidates causing serious adverse events, toxicities or other undesirable side effects; the outcome of preclinical testing and
early clinical trials not being predictive of the success of later clinical trials and the risks related to the results of Edgewise's
clinical trials not satisfying the requirements of regulatory authorities; delays or difficulties in the enrollment and/or maintenance
of patients in clinical trials; risks related to failure to capitalize on other indications or product candidates; risks related to competition;
risks relating to interim, topline and preliminary data from Edgewise's clinical trials changing as more patient data becomes available;
risks related to failure to develop a proprietary drug discovery platform; risks related to exposure to additional risk if we develop
sevasemten and potential other programs in connection with other therapies; risks related to production of drugs by Edgewise's third-party
manufacturers; risks related to changes in methods of product candidate manufacturing or formulation; risks related to not achieving adequate
market acceptance; risks related to the patient population for our product candidates having a small patient population; risks related
to the regulatory approval processes of domestic and foreign authorities being lengthy, time consuming and inherently unpredictable; risks
relating to disruptions at the FDA, the SEC and other government agencies; risks relating to Edgewise's ability to attract and retain
highly skilled executive officers and employees; Edgewise's ability to obtain and maintain intellectual property protection for its product
candidates; Edgewise's reliance on third parties; risks related to future acquisitions or strategic partnerships; risks related to general
economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section
entitled "Risk Factors" in documents that Edgewise files from time to time with the U.S. Securities and Exchange Commission.
These forward-looking statements are made as of the date of this press release, and Edgewise assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as
Behrad Derakhshan, Ph.D., Chief Operating Officer